多发性骨髓瘤患者血清中LncRNA PRAL的表达及与临床病理参数和预后的关系

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (916 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究多发性骨髓瘤（MM）患者血清长链非编码RNA（LncRNA）PRAL的表达及与临床病理参数和预后的关系。方法选取2016年1月—2017年1月南通大学第二附属医院（以下简称“我院”）诊治的82例MM患者的临床资料为病例组，以我院同期诊治的患其他血液疾病患者50例作为病例对照组，51名我院同期健康查体的人群作为健康对照组。应用荧光实时定量PCR检测各组血清中LncRNA PRAL的表达，统计学分析各组间表达差异及与MM临床病理特征间的关系。以血清LncRNA PRAL表达水平的均值2.125为界，将82例MM患者分为高LncRNA PRAL表达组40例和低LncRNA PRAL表达组42例，比较两组的治疗效果。Kaplan-Meier生存分析（Log-rank检验）不同LncRNA PRAL表达水平患者的预后差异。结果病例组LncRNA PRAL的表达明显低于病例对照组及健康对照组（P ＜ 0.05）。高国际分期系统（ISS）分期的MM患者血清中LncRNA PRAL表达水平明显低于低ISS分期的MM患者（P ＜ 0.05），而不同年龄、性别、诊断分型、Durie-Salmon分期、血乳酸脱氢酶、血钙及血红蛋白水平患者血清中LncRNA PRAL的相对表达量差异无统计学意义（均P ＞ 0.05）。病例组LncRNA PRAL高表达组患者的疗效优于LncRNA PRAL低表达组（P ＜ 0.05）。低LncRNA PRAL表达组3年总体生存率明显低于高LncRNA PRAL表达组，平均生存时间明显短于高LncRNA PRAL表达组（P ＜ 0.05）。结论 MM患者血清中LncRNA PRAL表达降低，血清中LncRNA PRAL低表达与高ISS分期及患者不良预后有关，有可能成为评估MM预后的重要指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张李玉顾喆贇周晓丹王铃陶健

关键词 ：多发骨髓瘤, LncRNA PRAL, 临床病理特征, 预后

Abstract：Objective To study the expression of long-chain non-coding RNA (LncRNA) PRAL in patients with multiple myeloma (MM) and its relationship with clinicopathological parameters and prognosis. Methods The clinical data of 82 patients with MM diagnosed and treated in the Second Affiliated Hospital of Nantong University (hereinafter referred to as “our hospital”) from January 2016 to January 2017 were selected as case group, 50 patients with other blood diseases in the same period in our hospital were selected as case control group, and 51 persons with physical examination in the same period in our hospital were taken as healthy control group. Quantitative real-time PCR was used to detect the expression of serum LncRNA PRAL of each group, and the expression difference of each group and their relationship with clinicopathological characteristics were statistically analyzed. According to the mean value of serum LncRNA PRAL expression of 2.125, 82 MM patients were divided into high LncRNA PRAL expression group (40 cases) and low LncRNA PRAL expression group (42 cases), the curative effect of the two groups was compared. The prognostic differences in patients with different LncRNA PRAL expression levels were analyzed by Kaplan-Meier survival analysis (Log-rank test). Results The expression of LncRNA PRAL in the case group was significantly lower than the case control group and the healthy control group (P ＜ 0.05). The expression of serum LncRNA PRAL of MM patients with high International staging system (ISS) stage was significantly lower than that in MM patients with low ISS stage (P ＜ 0.05), while the relative expression of serum LncRNA PRAL of patients with different age, gender, diagnostic typing, Durie-Salmon stage, blood lactate dehydrogenase, blood calcium and hemoglobin levels were not statistically significant (all P ＞ 0.05). The curative effect of patients with high expression of LncRNA PRAL was better than that of patients with low expression of LncRNA PRAL (P < 0.05). The 3-year overall survival rate of low LncRNA PRAL expression group was significantly lower than high LncRNA PRAL expression group, and the average survival time was significantly shorter than high LncRNA PRAL expression group(P ＜ 0.05). Conclusion The expression of serum LncRNA PRAL of MM patients is reduced. The low expression of serum LncRNA PRAL is related to the higher ISS stage and the poor prognosis of patients, and may become an important indicator for evaluating the prognosis of MM.

Key words： Multiple myeloma Long-chain non-coding RNA PRAL Clinicopathological characteristics Prognosis

基金资助:江苏省自然科学基金资助项目（2017MS0227）。

通讯作者: 陶健（1978.2-），男，硕士，副主任医师；研究方向：多发性骨髓瘤。

作者简介: 张李玉（1989.10-），女，硕士；研究方向：多发性骨髓瘤。

引用本文:

张李玉顾喆贇周晓丹王铃陶健. 多发性骨髓瘤患者血清中LncRNA PRAL的表达及与临床病理参数和预后的关系[J]. 中国医药导报, 2020, 17(34): 39-42,47.
ZHANG Liyu GU Zheyun ZHOU Xiaodan WANG Ling TAO Jian. Expression of LncRNA PRAL in serum of patients with multiple myeloma and its relationship with clinicopathological parameters and prognosis. 中国医药导报, 2020, 17(34): 39-42,47.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I34/39

[1] 宋丽婷，王芳，赵云，等.多发性骨髓瘤及其所在微环境的研究[J].临床合理用药杂志，2018，11（5）：179-180.
[2] 林薇，梁月雄，莫淑宜.化疗序贯CIK细胞输入对老年多发性骨髓瘤患者免疫、炎症因子的影响[J].中国医师杂志，2020，22（2）：275-277.
[3] 李强.多发性骨髓瘤骨病发生机制研究进展[J].医学综述，2016，22（9）：1697-1700.
[4] Wang H，Wang J，Liang CF，et al. Expression of Long Non-Coding RNA PRAL as a Potential Biomarker for Diagnosis in Non-Small-Cell Lung Cancer Patients is Associated with the Inhibition of Cell Proliferation and Metastasis [J]. Clin Lab，2018，64（9）：1341-1348.
[5] Zhou CC，Yang F，Yuan SX，et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma [J]. Hepatology，2016，63（3）：850-863.
[6] 温一阳，白冰，胡晓舒.长链非编码RNA PRAL在多发性骨髓瘤患者中的表达及其临床意义[J].中国实验血液学杂志，2020，28（1）：185-190.
[7] International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies，multiple myeloma and related disorders：a report of the International Myeloma Working Group [J]. Br J Haematol，2003，121（5）：749-757.
[8] Greipp PR，San Miguel J，Durie BG，et al. International staging system for multiple myeloma [J]. J Clin Oncol，2005，23（25）：6281.
[9] 张之南.血液病诊断及疗效标准[M].北京：科学出版社，2007.
[10] Gratwohl A. The EBMT risk score [J]. Bone Marrow Transplant，2012，47（6）：749-756.
[11] 郁子馨.老年多发性骨髓瘤的临床表现及护理方法及效果[J].全科口腔医学电子杂志，2020，7（3）：81，86.
[12] 史欢欢，田晔，李斌，等.长链非编码RNA的作用机制[J].生命科学研究，2018，22（3）：229-234.
[13] 纪伟，吴洪坤，周琳.多发性骨髓瘤非编码RNA的研究进展[J].检验医学，2018，33（3）：264-268.
[14] 王海玲，李东霞.LncRNA与恶性肿瘤侵袭转移研究进展[J].现代肿瘤医学，2018，26（13）：2114-2117.
[15] 孙金旗，马佳康，任凯凯，等.TCGA数据库中肝癌相关差异长链非编码RNA筛选和功能预测[J].胃肠病学和肝病学杂志，2019，28（2）：147-153.
[16] 张晓丽，陈伟强，王烈峰.长链非编码RNA的功能与人类重大疾病的相关性[J].赣南医学院学报，2019，39（4）：410-416.
[17] 周传传.拷贝数变异相关长链非编码RNA对肝癌发生发展的影响及机制研究[D].上海：第二军医大学，2013.
[18] 范凡，冯继锋.长链非编码RNA在肿瘤耐药中的研究进展[J].现代肿瘤医学，2018，26（22）：176-181.
[19] Jariwala N，Sarkar D. Emerging role of lncRNA in cancer：a potential avenue in molecular medicine [J]. Ann Transl Med，2016，4（15）：286.
[20] Su P，Wang F，Qi B，et al. P53 Regulation-Association Long Non-Coding RNA （LncRNA PRAL） Inhibits Cell Proliferation by Regulation of P53 in Human Lung Cancer [J]. Med Sci Monit，2017，23（1）：1751-1758.
[21] Xiao G，Li Y，Wang Y，et al. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity [J]. Exp Cell Res，2018，370（2）：254-263.
[22] Zuo C，Wang Z，Lu H，et al. Expression profiling of lncRNAs in C3H10T1/2 mesenchymal stem cells undergoing early osteoblast differentiation [J]. Mol Med Rep，2013，8（2）：463-467.
[23] Feo F，Simile MM，Pascale RM. Focal loss of long non-coding RNA-PRAL，as determinant of cell function and phenotype of hepatocellular carcinoma [J]. Ann Transl Med，2016，4（9）：183-189.
[24] Li D，Li H，Yang Y，et al. Long Noncoding RNA Urothelial Carcinoma-Associated 1 Promotes the Proliferation and Metastasis of Human Lung Tumor Cells by Regulating MicroRNA-144 [J]. Oncol Res，2018，26（4）：537-546.
[25] Zhu FF，Zheng FY，Wang HO，et al. Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer [J]. Pathol Oncol Res，2018， 24（2）：419-425.